Neonc Technologies
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Neonc Technologies sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Neonc Technologies: 3 sponsored US clinical trials, 3 recruiting.
Neonc Technologies sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Residual, Progressive or Recurrent Grade II or III Meningioma, with 1 trials.
Upper-quartile sponsor footprint
Neonc Technologies sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379
NEO100 and High-Grade Meningioma
NCT05023018
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
NCT02704858
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Neonc Technologies pipeline
3 recruiting of 3 indexed (100% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Residual, Progressive or Recurrent Grade II or III Meningioma (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Neonc Technologies: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Neonc Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Neonc Technologies page
3 registered trials is a research-attention snapshot, not an endorsement of Neonc Technologies or any single study.
- 3 of Neonc Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Residual, Progressive or Recurrent Grade II or III Meningioma is the condition Neonc Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Residual, Progressive or Recurrent Grade II or III Meningioma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Neonc Technologies pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.